Myopericarditis following COVID-19 mRNA vaccination.

We read the publication on “Risk of Myopericarditis following COVID‐19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods.” The true incidence of myopericarditis, according to Sharff et al., is significantly greater than the rate reported to US advisory committees in the fall of 2021. We concur that the true incidence of myopericarditis may differ from what has been reported. According to Sharff et al, there could be a higher occurrence. This could be attributed to cases with minor symptoms that go unnoticed. On the other hand, the actual rate of occurrence could be lower. A pre‐vaccination cardiac issue could occur and be misinterpreted as a COVID‐19 vaccine‐related adverse event. There should also be a system in place to rule out any other coexisting medical issues, such as a concomitant viral infection, which could induce a cardiac problem following immunization.

FUNDING INFORMATION

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest.